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Epidermal growth factor receptor (EGFR) gene mutations and increased copy numbers are considered as predictors of response to
EGFR tyrosine kinase inhibitors (EGFR-TKI) in non-small-cell lung cancer (NSCLC). Lung cancer diagnosis is often based on cytology
alone. However, almost all published data on EGFR gene analyses were obtained from biopsies. This study tested the feasibility of
EGFR gene analyses on cytological specimens. Eighty-four cytological specimens from NSCLCs were prospectively analysed for EGFR
gene mutation in exons 18–21 and EGFR gene copy numbers were evaluated by fluorescence in situ hybridisation (FISH). A FISH-
positive result was defined according to the criteria by Cappuzzo et al established for biopsies of NSCLCs. Fluorescence in situ
hybridisation results of cytological specimens were compared to the FISH results on matching biopsies (n¼33). Initial diagnosis of
NSCLC was solely based on cytology in 37 out of 84 (44.0%) patients. Out of 80 NSCLCs, 6 (7.5%) showed EGFR gene mutations.
Out of 67 cancers, 45 (67.2%) were FISH positive on cytological specimens. Comparison of FISH showed a FISH-positive result in 21
out of 33 (63.6%) cytological specimens but in only 8 out of 33 (24.2%) matched biopsies. Epidermal growth factor receptor gene
analyses are well applicable to cytological specimens. The high FISH-positive rate of NSCLC on cytological specimens contrasts with
the low rate on biopsies when previously suggested criteria are used. New criteria for a positive EGFR FISH status to predict response
to therapy with EGFR-TKI need to be defined for cytological specimens.
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Despite strong therapeutic efforts, the overall 5-year survival rate
of patients with lung cancer is only 15% without having improved
over the last 30 years emphasising the need for new therapies
(Jemal et al, 2006).
The epidermal growth factor receptor (EGFR) is known to play a
role in the development and progression of cancer, and small
molecular EGFR tyrosine kinase inhibitors (EGFR-TKI), including
gefitinib (Iressa
s; Astra Zeneca, Macclesfield, UK) and erlotinib
(Tarceva
s; OSI Pharmaceuticals Inc., Melville, NY, USA), are
available (Arteaga, 2002; Meert et al, 2002; Schlessinger, 2002;
Herbst and Bunn, 2003).
Somatic mutations within the tyrosine kinase domain of the
EGFR gene prevail in a subset of non-small-cell lung cancers
(NSCLC). These mutations are preferentially found in women, east
Asians, never smokers and adenocarcinomas, often with a
bronchioloalveolar histology (Fukuoka et al, 2003; Kris et al,
2003; Lynch et al, 2004; Miller et al, 2004; Paez et al, 2004; Perez-
Soler et al, 2004; Eberhard et al, 2005; Shepherd et al, 2005; Tsao
et al, 2005). Initial retrospective studies showed an average
response rate to EGFR-TKI of 75% for NSCLC with EGFR
mutations that contrasted with a low response rate of o10% for
tumours with wild-type EGFR gene (Riely et al, 2006). These
results were subsequently confirmed in prospective studies (Riely
et al, 2006). Since response to EGFR-TKI is not fully restricted to
patients with EGFR-mutated NSCLC suggests that additional
molecular mechanism may be involved (Tsao et al, 2005). In fact,
a high EGFR gene copy number detected by fluorescence in situ
hybridisation (FISH) was also shown to predict improved survival
after EGFR-TKI therapy (Cappuzzo et al, 2005; Hirsch et al, 2005).
A considerable fraction of NSCLCs is diagnosed solely by
cytology, and the relative paucity of tumour cells on these
specimens is a challenge for molecular analyses (Sequist et al,
2007). Since almost all of the published data on EGFR mutation
and gene copy number analyses were made on biopsy material, the
goal of this study was to test whether such EGFR gene analyses are
feasible on cytological specimens of NSCLCs in a diagnostic
setting.
MATERIALS AND METHODS
Cytology and biopsy specimens
A consecutive series of 84 cytological specimens with NSCLC
diagnosed during November 2004 to January 2006 was entered into
the study. Sixty-five specimens were from primary tumours and 19
from regional lymph node metastases of the mediastinum. The
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sspecimens included 35 transbronchial fine needle aspirates, 15
bronchial washings, 13 bronchial brushes, 5 bronchoalveolar
lavages and 16 pleural effusions.
The specimens were processed according to routine procedures,
using Delaunay’s solution as a fixative. They were stained according
to Papanicolaou and permanently mounted with coverslips.
In 33 patients, a matched biopsy of the NSCLC was available for
comparative analysis. Biopsies were fixed in 4% buffered formalin,
and paraffin-embedded biopsies were cut into 4mm sections and
stained with haematoxylin and eosin. In 26 of these 33 paired
specimens, both cytology and biopsy were from the primary
tumour sites (nine bronchial washings with nine bronchial
biopsies; six bronchial brushes with four bronchial biopsies, one
pneumonectomy and one pleural biopsy; five transbronchial fine
needle aspirates of the lung with three bronchial biopsies and two
lobectomies; four pleural effusions with two pleural biopsies,
one bronchial biopsy and one lung examined at autopsy; two
bronchoalveolar lavages with one bronchial biopsy and one
pneumonectomy).
Sequence analysis of the EGFR gene
Cancer cells from Papanicolaou-stained cytological specimens and
from haematoxylin–eosin-stained tissue sections were selectively
dissected under visual control using laser microdissection in
combination with a laser pressure catapulting system according to
the manufacturer’s guidelines (PALM
s MicroBeam, Microlaser
Technologies GmbH, Bernried, Germany). Laser energy catapulted
cells were collected in the cap of a 0.5ml plastic tube containing
80mlo f1   PCR buffer (Applied Biosystems, Foster City, CA,
USA). A 20ml portion of proteinase K was added and incubated
overnight at 561C. The enzyme was inactivated by heating at 951C
for 10min. In order to avoid recently described false-positive point
mutations by polymerase (Marchetti et al, 2006), we performed
two independent multiplex PCRs using 5ml of this solution, each as
a template followed by a second multiplex PCR.
The first multiplex PCR contained all forward and reverse
primers for the EGFR exons 18, 19, 20 and 21 (Table 1). For the
second multiplex PCR with nested and seminested primers
(Table 1), 1ml from the first multiplex PCR was used as a template.
For the first and the second PCRs, 50 PCR cycles were
performed using the hot start AmpliTaq Gold polymerase (Applied
Biosystems) under the following conditions: denaturation: 20s at
951C, annealing: 10s at 591C, elongation: 40s at 721C.
After exon amplification, unused primers were cleaned up with
ExoSAP-IT (USB Corporation, Cleveland, OH, USA). After
inactivating the enzyme at 801C for 15min, we used 0.5mla s
template for the sequencing PCR. Sequencing was performed in
forward and reverse direction for every exon.
The sequence amplicons were detected by capillary electro-
phoresis with laser-induced fluorescence detection (3130 Genetic
Analyzer, Applied Biosystems/Hitachi Inc., Foster City, CA, USA).
The resulting four visualised sequences (chromatograms) per exon
were analysed using SeqScape 2.5 Software (Applied Biosystems).
The sequence analysis of the EGFR gene was considered evaluable
if at least two chromatograms of every exon and at least one in
each separate DNA isolate were readable.
Specimen pretreatment and FISH assay
A hybridisation target area of 18 18mm to 24 50mm depend-
ing on cellularity was selected and permanently marked with a
diamond pen. The exact locations of the carcinoma cells were
saved by a relocation software (Mark&Find Module; Carl Zeiss
Vision GmbH, Hallbergmoos, Germany) connected to an auto-
mated stage (Type 00-24-473-0000; Carl Zeiss AG, Oberkochen,
Germany) on a Zeiss Axioplan 2 epifluorescence microscope (Carl
Zeiss GmbH Jena, Jena, Germany). Before uncovering and
hybridisation, a representative cell group was photographed with
a digital camera (AxioCam Color, Type 412–312).
The commercially available LSI EGFR SpectrumOrange/CEP 7
SpectrumGreen dual-colour probe set (Vysis Inc., Abbott Laboratories,
Downers Grove, IL, USA) was used. It includes directly labelled DNA
FISH probes for the EGFR gene (7p12, SpectrumOrange) and the
centromere of chromosome 7 (at 7p11.1–q11, SpectrumGreen).
Fluorescence in situ hybridisation on cytological specimens was
performed according to the recommendations of the manufacturer
with minor modifications, as described previously (Savic et al,2 0 0 6 ) .
For FISH on biopsies, we used haematoxylin–eosin-stained
tissue sections using our previously described standard FISH
protocol (Stadlmann et al, 2006). No separate procedure for
destaining was required.
Enumeration of FISH signals
Enumeration of FISH signals was performed at a magnification of
 630 after automatic relocation of the cancer cells by a relocation
software in the DAPI single-bandpass filter set on a fluorescence
microscope. Nuclear signal enumeration was only performed on
Table 1 Primers used for the EGFR gene mutation analysis for the first and the second PCR
Primers
EGFR gene Forward Reverse
Exon 18
First PCR GCATGGTGAGGGCTGAGGTGA CCCCACCAGACCATGAGAGGC
Second PCR ACCCTTGTCTCTGTGTTCTTGTCCC GCCCAGCCCAGAGGCCTGTG
Exon 19
First PCR TGCCAGTTAACGTCTTCCTTC CCACACAGCAAAGCAGAAAC
Second PCR AACGTCTTCCTTCTCTCTCTG CCACACAGCAAAGCAGAAAC
Exon 20
First PCR CCACCATGCGAAGCCACACTGA TCCTTATCTCCCCTCCCCGTATCTC
Second PCR CCATGCGAAGCCACACTGACGT CCCCTCCCCGTATCTCCCTTCC
Exon 21
First PCR AGCTTCTTCCCATGATGATCTGTCC GGCAGCCTGGTCCCTGGTGTC
Second PCR TCCCATGATGATCTGTCCCTCACA CAGGAAAATGCTGGCTGACCTAAAG
EGFR¼epidermal growth factor receptor; PCR¼polymerase chain reaction.
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signals. A maximum of 100 cancer cells were scored.
NSCLCs were defined as FISH positive according to previously
defined criteria by Cappuzzo et al (2005): a FISH-positive result
was defined as presence of ‘high polysomy’ (X4 EGFR gene copies
per nucleus in X40% of the analysed cancer cells) or of
amplification (presence of tight EGFR gene clusters and a ratio
of EGFR gene to chromosome of X2, or X15 EGFR gene copies per
nucleus in X10% of the analysed cancer cells).
Data analysis
Statistical tests included two-tailed Fisher’s exact, Pearson’s w
2 and
Wilcoxon signed-rank test. Statistical significance was defined as
Po0.05. Statistical analysis was performed with JMP 5.1 software
(SAS Institute, Cary, NC, USA). Receiver operating characteristic
(ROC) curve analysis was performed using the statistical software
R (v. 2.4.0) (Team, 2004).
RESULTS
Patient and tumour characteristics
Clinicopathological data of the 84 patients are summarised in
Table 2. Sixty-three (75.0%) patients had an inoperable UICC
(International Union Against Cancer) tumour stage IIIB, IV or a
recurrence. There was no significant difference in tumour
histology and tumour stage between male and female patients.
The diagnosis of lung cancer was solely based on cytology in 37
out of 84 (44.0%), and a simultaneous diagnosis of lung cancer by
cytology and biopsy was made in 34 out of 84 (40.5%) patients.
The remaining 13 (15.5%) NSCLC were initially diagnosed by
cytology and subsequently by biopsy obtained within a median of
20 days (ranging 8–54 days) after cytology.
EGFR gene sequencing and mutation status
Results of EGFR DNA mutation analysis and their associations
with clinicopathological data of the 84 patients are summarised in
Table 3. DNA sequencing was successful in 78 out of 84 (92.9%)
NSCLCs analysed from cytological specimens. We found four
EGFR gene mutations (one on a fine needle aspirate and three on
bronchial washings). Matched biopsies were available in three of
the six NSCLCs that were not evaluable for EGFR mutation.
Sequence analysis was repeated on these tissue specimens
revealing mutations in two of these, including a point mutation
in exon 21 (R832H) and a silent mutation in exon 20 (F795F),
respectively. The EGFR gene sequence of the third NSCLC was not
evaluable from the biopsy specimen either. Comparison of the 78
cases evaluable for EGFR gene sequencing with the 6 non-evaluable
ones revealed no significant differences in the mean microdissected
tumour cell areas or the estimated cell counts (data not shown).
In summary, 6 out of 80 (7.5%) NSCLCs showed EGFR
mutations: 4 diagnosed on cytological specimens and 2 on biopsy
specimens. These mutations included the well-described deletion
E746-A750 in exon 19 and the point mutation L858R in exon 21 as
well as the previously described point mutation R832H in exon 21
and the insertion ASV 770–772 in exon 20 (Shigematsu et al, 2005;
Giaccone et al, 2006).
Four of the six NSCLCs with EGFR mutation were from female
patients.
Table 4 shows a summary of NSCLCs EGFR mutations,
including mutation types, EGFR FISH results and patient
characteristics.
Estimate of the minimal number of cells needed for EGFR
gene sequencing
In order to evaluate the minimal number of cells for successful
EGFR DNA sequence analysis, we compared the quality of DNA
chromatograms from exons 18, 19, 20 and 21 of the EGFR gene
obtained from 30, 50 and 100 cancer cells. The cells were dissected
from five cytological specimens from NSCLC with known EGFR
mutation status. Four of these NSCLCs had no EGFR mutation and
Table 2 Patient and tumour characteristics of NSCLCS analysed for
EGFR mutation and gene copy number
Characteristics Patients (%)
Total 84
UICC stage
I–IIIA 20 (23.8)
IIIB–IV 58 (69.0)
Recurrence 5 (6.0)
No information 1 (1.2)
Cancer type
NSCLC, NOS 26 (31.0)
AC 51 (60.7)
SCC 6 (7.1)
LCNEC 1 (1.2)
AC¼adenocarcinoma; EGFR¼epidermal growth factor receptor; LCNEC¼large
cell neuroendocrine carcinoma; NSCLC, NOS¼non-small-cell lung carcinoma, not
otherwise specified; SCC¼squamous cell carcinoma; UICC¼International Union
Against Cancer.
Table 3 Association between EGFR mutation and FISH status and
clinicopathological characteristics of NSCLCs
EGFR mutation
a EGFR FISH status
Characteristics
Present
(%)
Absent
(%)
Positive
(%)
Negative
(%)
Total 6 (7.5) 74 (92.5) 45 (67.2) 22 (32.8)
Gender
Male (n¼55) 2 (3.6) 53 (96.4) 32 (68.1) 15 (31.9)
Female (n¼25) 4 (16) 21 (84) 13 (65) 7 (35)
P 0.07 1.00
UICC stage
I–IIIA 2 (11.1) 16 (88.9) 7 (50) 7 (50)
IIIB–IV 3 (5.4) 53 (94.6) 35 (74.5) 12 (25.5)
Recurrence 0 5 2 (40) 3 (60)
No information 1 1
P (I–IIIA vs IIIB–IV) 0.59 0.11
Cancer type
NSCLC, NOS 3 (12.5) 21 (87.5) 12 (66.7) 6 (33.3)
AC 3 (6.1) 46 (93.9) 30 (66.7) 15 (33.3)
SCC 0 6 3 (75) 1 (25)
LCNEC 0 1 0 0
AC¼adenocarcinoma; EGFR¼epidermal growth factor receptor; FISH¼fluores-
cence in situ hybridisation; LCNEC¼large cell neuroendocrine carcinoma; NSCLC,
NOS¼non-small-cell lung carcinoma, not otherwise specified; SCC¼squamous cell
carcinoma; UICC¼International Union Against Cancer. Criteria for a positive FISH
result: presence of high polysomy (X4 EGFR gene copies per nucleus in X40% of the
analysed cancer cells) or of amplification (presence of tight EGFR gene clusters and a
ratio of EGFR gene to chromosome of X2, or X15 EGFR gene copies per nucleus in
X10% of the analysed cancer cells).
aThe results include two cases in which the EGFR
mutation was detected on the biopsy specimens.
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sone had a point mutation in exon 21 (L585R). The best result was
obtained with 100 analysed cells with 19 out of 20 evaluable
chromatograms, followed by 50 cells with 18 out of 20 evaluable
chromatograms. With 30 analysed cancer cells, only 12 chromato-
grams were evaluable. The differences in the evaluability between
the different cell counts were not statistically significant. The point
mutation in exon 21 (L858R) was identified with 30, 50 and 100
cells.
EGFR gene copy number
In 75 out of 84 (89.3%) specimens, a sufficient number of cancer
cells remained for FISH analysis after tumour cell dissection for
EGFR gene mutation analysis. Fluorescence in situ hybridisation
analysis was successful in 67 out of 75 (89.3%) specimens. The
mean number of scored cells was 70±32.7 (ranging 12–100; 95%
confidence interval (CI): 62.0–78.0). Fluorescence in situ hybridi-
sation was positive according to the criteria defined by Cappuzzo
et al (2005) in 45 out of 67 (67.1%) of the cytological specimens,
including 35 out of 67 (52.2%) NSCLCs with ‘high polysomy’ and
10 out of 67 (14.9%) with amplification.
Representative images of FISH-positive results are illustrated in
Figure 1.
A matched biopsy specimen was available in 33 patients for
comparative FISH analysis. The mean number of scored cells was
significantly higher in the biopsy specimens compared to the
cytology specimens (mean 88.6±17.6: ranging 43–100; 95% CI:
82.4–94.9 vs mean 66.1±31.6: ranging 12–100; 95% CI: 54.9–77.3;
Po0.01). Fluorescence in situ hybridisation was positive in 21
(63.6%) of these 33 cytological specimens, including 19 (57.6%)
cases with ‘high polysomy’ and 2 (6%) cases with amplification.
Fluorescence in situ hybridisation on biopsy specimens was
positive in only 8 out of 33 (24.2%) NSCLCs, including 5
(15.1%) with ‘high polysomy’ and 3 (9.1%) with amplification
(Table 5). The substantial difference in the FISH results between
the matched cytologies and biopsies was almost unchanged when
the analysis was restricted to the primary tumours (n¼26) after
exclusion of the regional lymph node metastases (P¼0.01). Thus,
the difference cannot be explained by a change of FISH status
during progression to metastasis. The number of scored cells
remained significantly higher in the biopsy specimens compared
to the cytology specimens.
Two amplified NSCLCs showed amplification both in the
cytology and in biopsy specimen. In another NSCLC EGFR gene
amplification was found in the biopsy but not in the cytological
specimen. A review of the slides revealed that the tumour cells in
Table 4 NSCLCs with EGFR gene mutation: summary of EGFR mutation types, FISH results and patient characteristics
Patient EGFR mutation EGFR FISH result Sex Age (years) UICC stage Diagnosis Smoking history
1 Exon 19 del E746-A750 Positive amplification Female 35 IV NSCLC No
2 Exon 20 Ins ASV 770–772 Positive amplification Female 68 IV AC Yes
3 Exon 20 F795F Positive high polysomy Male 71 —
a AC —
a
4 Exon 21 L858R Positive high polysomy Female 49 IV NSCLC Yes
5 Exon 21 R832H Negative Male 66 IIIA NSCLC Yes
6 Exon 21 R837R Negative Female 81 IIA NSCLC No
AC¼adenocarcinoma; del¼deletion; EGFR¼epidermal growth factor receptor; FISH¼fluorescence in situ hybridisation; ins¼insertion; NSCLC¼non-small-cell lung
carcinoma; UICC¼International Union Against Cancer.
aNo information.
AB
Figure 1 Representative images of FISH-positive results on cytological specimens (EGFR gene: red signals; chromosome 7: green signals). (A) Amplification
of the EGFR gene with tight EGFR gene clusters; (B) high polysomy of the EGFR gene in the cancer cells. FISH¼fluorescence in situ hybridisation;
EGFR¼epidermal growth factor receptor (see online version for colour figure).
Table 5 Association between EGFR FISH results in the cytological
specimens and matched biopsy specimens from all NSCLCs (n¼33) and
from the subgroup of primary NSCLCs without specimens from regional
lymph node metastases (n¼26)
Cytological
specimens (%)
Biopsy
specimens (%) P-value
Total 33 33
FISH positive 21 (63.6) 8 (24.2)
High polysomy 19 (57.6) 5 (15.1)
Amplification 2 (6) 3 (9.1)
FISH negative 12 (36.4) 25 (75.8)
o0.01
a
Primary tumour
b 26 26
FISH positive 16 (61.5) 7 (26.9)
High polysomy 14 (53.8) 4 (15.4)
Amplification 2 (7.7) 3 (11.5)
FISH negative 10 (38.5) 19 (73.1)
0.01
a
EGFR¼epidermal growth factor recepetor gene; FISH¼fluorescence in situ
hybridisation; NSCLC¼non-small-cell lung carcinoma.
aP-value for difference in
FISH positivity between cytology and biopsy.
bBoth cytology and biopsy from the
primary tumour site.
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sthe biopsy were much less differentiated than the cells in the
cytological specimen. This suggests that the discrepancy between
cytology and histology in this patient could be due to tumour
heterogeneity.
In order to synchronise the FISH status of cytological and
histological specimens, we tuned the threshold of a positive FISH
result for cytological specimens using ROC curve based on the 33
cases with matched specimens (Linden, 2006). Changing the
number of gene copies and the minimal percentage of cells in
cytological specimens would identify the ideal threshold with
maximal sensitivity and specificity. Applying the set of parameters
used for definition of ‘high polysomy’ on biopsies (X4 copies in
X40% of cells) to cytology resulted in a sensitivity, specificity,
positive predictive value (PPV), negative predictive value (NPV)
and k of 1.0, 0.45, 0.33, 1.0 and 0.26, respectively. The optimised
parameters obtained by the ROC curve for ‘high polysomy’ on
cytological specimens were X5 copies in X70% of cells. The
sensitivity, specificity, PPV, NPV and k were 0.67, 1.0, 1.0, 0.92 and
0.76 respectively.
Comparison between mutation and FISH status showed that
four of the six EGFR gene-mutated NSCLCs had a FISH-positive
result, including two with ‘high polysomy’ and two with
amplification. Epidermal growth factor receptor gene analysis was
mostly performed on cells from Papanicolaou-stained specimens
but also worked well in cases in which only immunostained slides
were available. The EGFR gene sequence was evaluable in 5 out of 6
specimens and FISH in 7 out of 10 specimens after immuno-
cytochemistry for TTF-1, or BerEp4, or cytokeratine 7, or
cytokeratine 20.
DISCUSSION
In this study, we demonstrate that a comprehensive EGFR gene
analysis for prediction of response to EGFR-TKI in NSCLC is well
feasible in routinely processed cytological specimens. In most
patients, small biopsies or cytological specimens must suffice for
both morphological diagnosis and predictive marker analyses.
Importantly, as in our series, NSCLC is often diagnosed by
cytology alone (Rivera et al, 2003). In contrast, most previous
studies on EGFR gene mutations or copy number analyses in lung
cancer were based on resection specimens or biopsy material. The
clinical effect of EGFR-TKI in a proportion of patients with NSCLC
is associated with several molecular alterations, including EGFR
mutations and increased copy number of the EGFR gene, although
the relative importance of the alterations remains controversial
(Cappuzzo et al, 2006; Dziadziuszko et al, 2006; Riely et al,
2006).
We found EGFR mutations in 7.5% of the patients. This is in
accordance with previous studies in Caucasian patients where the
prevalence ranged from 4.5 to 14.1% (Kosaka et al, 2004; Marchetti
et al, 2005; Sasaki et al, 2005; Tokumo et al, 2005; Yang et al, 2005).
For mutation analysis, enrichment of morphologically identified
cancer cells is crucial in order to avoid dilution of tumour DNA
with non-mutated normal DNA from benign cells that often
outnumber the malignant cells. This can readily be achieved by
laser microdissection. We were able to determine the DNA
sequence from as few as 30 tumour cells.
Cappuzzo et al (2005) were the first to propose a strong
predictive role of EGFR gene copy number for response to therapy
with EGFR-TKI in NSCLC. They found a positive EGFR FISH status
defined as ‘high polysomy’ or ‘amplification’ in 32.4% of biopsies
from 102 patients with NSCLC being an independent predictor of
response to erlotinib. The importance of EGFR gene copy number
for therapy response to EGFR-TKI has subsequently been
confirmed by several studies (Bell et al, 2005; Eberhard et al,
2005; Tsao et al, 2005; Hirsch et al, 2006). However, all of these
previous studies examining EGFR FISH were based solely on
histological tissue sections and did not consider cytological
specimens. This may have been due to difficulties in differentiating
reactive cells from admixed cancer cells after hybridisation. In fact,
we regard automated relocation of carcinoma cells identified in
Papanicolaou-stained specimens as a prerequisite of FISH analysis
in cases in which cancer cells are admixed with a high proportion
of benign cells. Disregarding cytological specimens in a previous
randomised study on erlotinib in 731 NSCLCs may be one of the
reasons why the percentage of specimens used for mutation and
FISH analyses was as low as 27 and 30%, respectively (Shepherd
et al, 2005; Tsao et al, 2005).
Applying the criteria of Cappuzzo et al in our study revealed a
high FISH-positive rate of NSCLC in cytological specimens (63.6%)
that contrasted with a low rate in matched biopsy specimens
(24.2%). The latter was in line with the prevalence of FISH
positivity found in previous studies (Table 6). The discrepancy
between cytology and histology is explained by the fact that a
proportion of the cell nuclei on biopsy tissue sections are
truncated, leading to a lower number of gene signals per nucleus.
In contrast, the cell nuclei on the cytological specimens remain
intact and contain the true number of gene copies. The
discrepancy remained almost unchanged when analysing only
primary tumours, dispelling gene copy differences due to tumour
heterogeneity between primary tumours and locoregional meta-
stases. Thus, thresholds of FISH positivity defined on histological
sections cannot directly be translated to cytological specimens.
This is especially true for low-copy-number gains such as the
category of ‘high polysomy’, where at least four signals per nucleus
Table 6 Comparison of published EGFR FISH results using the criteria proposed by Cappuzzo et al (2005) with present data
Study
Number of
evaluated NSCLC Number of scored cells
FISH
positive (%)
Balanced (‘high’)
polysomy (%) Amplification (%)
Cappuzzo et al (2005)
a 102 —
b 33 20 13
Tsao et al (2005)
a 125 33–100 45 34 11
Hirsch et al (2005)
a 81 X100 32 —
b —
b
Hirsch et al (2006)
a 370 —
b 31 17 14
Jeon et al (2006)
a 262 —
b 30.2 19.1 11.1
Ichihara et al (2007)
a 75 X100 41.3 25.3 16
Present study
Histology 33 43–100 (mean: 88.6±17.6) 24.2 15.1 9.1
Cytology 67 12–100 (mean: 66.1±31.6) 67.1 52.2 14.9
EGFR¼epidermal growth factor receptor gene; FISH¼fluorescence in situ hybridisation; NSCLC¼non-small-cell lung carcinoma. Criteria for a positive FISH result: presence of
high polysomy (X4 EGFR gene copies per nucleus in X40% of the analysed cancer cells) or of amplification (presence of tight EGFR gene clusters and a ratio of EGFR gene to
chromosome of X2, or X15 EGFR gene copies per nucleus in X10% of the analysed cancer cells).
aAll cited FISH analyses were performed on histological specimens.
bNo
information.
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sare required in at least 40% of the cells. A proportion of tumour
cells with three signals or two signals in histological sections would
in fact contain four signals if the nuclei were not truncated. Thus,
some of these cases would cross the threshold for FISH positivity if
the nuclei were intact. In contrast, nuclear truncation does not
affect the ability to detect high-level amplifications, as previously
shown in cytohistological comparisons of HER-2 FISH analysis in
breast cancer (Bozzetti et al, 2002; Gu et al, 2005). This concurs
with our results where the difference between histology and
cytology was greatest in the category of ‘high polysomy (57.6 vs
15.2%, Po0.01), whereas the prevalence of amplification was
comparably low (6 vs 9.1%). An optimised threshold of X5 gene
copies in X70% of cells as calculated from ROC curve analysis
could substantially improve the specificity and PPV of FISH in
cytology when the FISH result of histology was used as a gold
standard. However, this was at the cost of reduced sensitivity to a
low 67%. There have been previous attempts to compensate for the
discrepancies between whole-cell preparations and tissue sections
for more accurate enumeration of FISH signals (Berezuk et al,
2001). However, the proposed correction factors based on the cell
diameter are limited by the variability of nuclear size and shape in
cancer cells, which makes this approach insufficient in a diagnostic
setting.
Cytological specimens and matched biopsies are not always
from the identical tumour area. Therefore, it is possible that the
difference in EGFR FISH status between cytology and biopsy in
this study might be partly attributable to heterogeneity. However,
it is very unlikely that tumour heterogeneity had a unidirectional
effect towards a 3.8-fold higher rate of ‘high polysomy’ in cytology
than in biopsy (57.6 vs 15.1%). It is similarly unlikely that the
lower mean number of tumour cells available for EGFR FISH
analysis in cytological specimens selected for ‘high polysomy’. A
study on a larger series of matched histological and cytological
specimens is under way to investigate the impact of tumour
heterogeneity and cell count on the EGFR FISH status, and to
define better criteria of a positive EGFR FISH result in cytological
specimens.
It is becoming increasingly important to analyse prognostic and
predictive markers in tumour biopsies as exemplified by EGFR
gene analysis in NSCLC. This is also true for cytological specimens
that are often the only source of cells from primary tumours or
distant metastatic sites. When dealing with limited cell material in
a diagnostic setting, the morphological diagnosis still has priority
over molecular analyses. Here, we show that comprehensive
molecular data can be obtained even from few cancer cells on
diagnostic cytological specimens, which is facilitated by laser
microdissection and automated relocation. Our data challenge the
recently expressed opinion that the ‘widespread use of mutational
analysis is currently hindered by the routine use of very small
fragments of tissue to establish the diagnosis of NSCLC’ (Riely
et al, 2006). Importantly, standard staining such as Papanicolaou
does not interfere with FISH and DNA analysis by PCR, and these
methods can even be applied to previously immunostained
specimens. This is important since immunocytochemical assess-
ment of proteins such as EGFR or p-Akt may also be of value in
predicting response to EGFR-TKI (Cappuzzo et al, 2004; Tsao et al,
2005). Notably, these techniques and tools are not restricted to
EGFR analysis and also set the stage for the analysis of future
therapeutic targets.
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